These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8763058)

  • 1. [Test for occult blood in feces: a method for reducing the mortality from colorectal cancer?].
    Faivre J; Tazi MA
    Gastroenterol Clin Biol; 1996; 20(3):225-7. PubMed ID: 8763058
    [No Abstract]   [Full Text] [Related]  

  • 2. [Epidemiology and screening of colorectal cancer].
    Dancourt V; Faivre J
    Rev Prat; 2004 Jan; 54(2):135-42. PubMed ID: 15086055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Faecal occult blood screening and reduction of colorectal cancer mortality: a case-control study.
    Faivre J; Tazi MA; El Mrini T; Lejeune C; Benhamiche AM; Dassonville F
    Br J Cancer; 1999 Feb; 79(3-4):680-3. PubMed ID: 10027349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Does yearly fecal exam for occult blood lower colorectal cancer mortality?].
    Gerbes L; Jüngst D; Köbberling J
    Z Gastroenterol; 1994 Oct; 32(10):603-6. PubMed ID: 7716998
    [No Abstract]   [Full Text] [Related]  

  • 5. Fecal-occult-blood test screening for colorectal cancer.
    Zacks M
    J Fam Pract; 1997 Mar; 44(3):247-8. PubMed ID: 9071239
    [No Abstract]   [Full Text] [Related]  

  • 6. [Annual occult blood tests lower intestinal cancer mortality].
    Gnauck R
    Wien Med Wochenschr; 1993; 143(13):352. PubMed ID: 8237026
    [No Abstract]   [Full Text] [Related]  

  • 7. Colorectal cancer mortality in two areas of Tuscany with different screening exposures.
    Costantini AS; Martini A; Puliti D; Ciatto S; Castiglione G; Grazzini G; Zappa M
    J Natl Cancer Inst; 2008 Dec; 100(24):1818-21. PubMed ID: 19066268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mass screening for colorectal cancer using occult blood studies. From theoretic efficacy to generalized practice].
    Launoy G; Herbert C
    Rev Epidemiol Sante Publique; 1997 Apr; 45(2):177-8. PubMed ID: 9221447
    [No Abstract]   [Full Text] [Related]  

  • 9. [To screen the colorectal cancer. An organized process].
    Chedru MF; Dumont C; Bloch J; Lequellec-Nathan M; Postel-Vinay N; Coquin Y; Dab W
    Rev Prat; 2004 Jan; 54(2):121-2. PubMed ID: 15086052
    [No Abstract]   [Full Text] [Related]  

  • 10. [Does fecal occult blood screening result in decreased mortality from large intestine cancer?].
    Porschen R; Haack G
    Z Gastroenterol; 1997 Jul; 35(7):595-6. PubMed ID: 9340935
    [No Abstract]   [Full Text] [Related]  

  • 11. [Mass screening for colorectal cancer].
    Faivre J; Tazi MA; Launoy G
    Rev Epidemiol Sante Publique; 1996; 44 Suppl 1():S7-14. PubMed ID: 8935859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mass screening of colorectal cancer by general practitioners in France: what is the real target population?].
    Desoubeaux N; Herbert C; Launoy G; Vallée JP; Bouvier V; Maurel J; Née E; Gignoux M
    Gastroenterol Clin Biol; 1997; 21(10):760-3. PubMed ID: 9587517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fecal blood screening lowers mortality from intestinal cancer].
    Gnauck R
    Leber Magen Darm; 1994 Mar; 24(2):55-6. PubMed ID: 8196465
    [No Abstract]   [Full Text] [Related]  

  • 15. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevention of colorectal carcinoma. Annual hemoccult test and sigmoidoscopy every 5 years].
    Rosenbaum A; Riemann JF
    MMW Fortschr Med; 2000 Aug; 142(31-32):27-9. PubMed ID: 10992763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
    Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
    Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer.
    Lindholm E; Brevinge H; Haglind E
    Br J Surg; 2008 Aug; 95(8):1029-36. PubMed ID: 18563785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Randomized controlled trial of sequence mass screening program for colorectal cancer].
    Liu X; Zheng S; Chen K; Ma X; Zhou L; Yu H; Yao K; Chen K; Cai S; Zhang S
    Zhonghua Liu Xing Bing Xue Za Zhi; 2000 Dec; 21(6):430-3. PubMed ID: 11860828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in colorectal cancer mortality related to annual fecal occult blood screening--13 year follow-up of 46,000 subjects.
    Kita MW
    J Insur Med; 1993; 25(2):138-9. PubMed ID: 10146315
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.